In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...

Rubius Therapeutics, Inc. (RUBY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Rubius Therapeutics’ plan to revive its red blood cell therapy research with a new approach has run out of time and money, and the biotech is now looking to strike a deal to salvage what’s left of the ...

Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...

Rubius Therapeutics Inc. of Cambridge is set to announce Wednesday that it has raised $120 million — one of the largest biotech financing rounds this year — to develop a novel drug-making technology.

Rubius Therapeutics shares more than doubled during Monday's session after investors received the biotech firm's outline of results from early-stage tests of a potential cancer drug. The company said ...

Rubius Therapeutics on Wednesday priced its initial public offering at $23 a share, above the expected range of $20 to $22, according to Renaissance Capital. The biotech, which develops red blood ...

Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment derived from red blood cells, its maker Rubius Therapeutics said Monday. Rubius said the ...